Pub Date : 2015-07-01Epub Date: 2015-06-30DOI: 10.4111/kju.2015.56.7.487
Sangjun Yoo, Jeong Kon Kim, In Gab Jeong
Recently, imaging of prostate cancer has greatly advanced since the introduction of multiparametric magnetic resonance imaging (mpMRI). mpMRI consists of T2-weighted sequences combined with several functional sequences including diffusion-weighted imaging, dynamic contrast-enhanced imaging, and/or magnetic resonance spectroscopy imaging. Interest has been growing in mpMRI because no single MRI sequence adequately detects and characterizes prostate cancer. During the last decade, the role of mpMRI has been expanded in prostate cancer detection, staging, and targeting or guiding prostate biopsy. Recently, mpMRI has been used to assess prostate cancer aggressiveness and to identify anteriorly located tumors before and during active surveillance. Moreover, recent studies have reported that mpMRI is a reliable imaging modality for detecting local recurrence after radical prostatectomy or external beam radiation therapy. In this regard, some urologic clinical practice guidelines recommended the use of mpMRI in the diagnosis and management of prostate cancer. Because mpMRI is the evolving reference standard imaging modality for prostate cancer, urologists should acquire cutting-edge knowledge about mpMRI. In this article, we review the literature on the use of mpMRI in urologic practice and provide a brief description of techniques. More specifically, we state the role of mpMRI in prostate biopsy, active surveillance, high-risk prostate cancer, and detection of recurrence after radical prostatectomy.
{"title":"Multiparametric magnetic resonance imaging for prostate cancer: A review and update for urologists.","authors":"Sangjun Yoo, Jeong Kon Kim, In Gab Jeong","doi":"10.4111/kju.2015.56.7.487","DOIUrl":"https://doi.org/10.4111/kju.2015.56.7.487","url":null,"abstract":"<p><p>Recently, imaging of prostate cancer has greatly advanced since the introduction of multiparametric magnetic resonance imaging (mpMRI). mpMRI consists of T2-weighted sequences combined with several functional sequences including diffusion-weighted imaging, dynamic contrast-enhanced imaging, and/or magnetic resonance spectroscopy imaging. Interest has been growing in mpMRI because no single MRI sequence adequately detects and characterizes prostate cancer. During the last decade, the role of mpMRI has been expanded in prostate cancer detection, staging, and targeting or guiding prostate biopsy. Recently, mpMRI has been used to assess prostate cancer aggressiveness and to identify anteriorly located tumors before and during active surveillance. Moreover, recent studies have reported that mpMRI is a reliable imaging modality for detecting local recurrence after radical prostatectomy or external beam radiation therapy. In this regard, some urologic clinical practice guidelines recommended the use of mpMRI in the diagnosis and management of prostate cancer. Because mpMRI is the evolving reference standard imaging modality for prostate cancer, urologists should acquire cutting-edge knowledge about mpMRI. In this article, we review the literature on the use of mpMRI in urologic practice and provide a brief description of techniques. More specifically, we state the role of mpMRI in prostate biopsy, active surveillance, high-risk prostate cancer, and detection of recurrence after radical prostatectomy. </p>","PeriodicalId":17819,"journal":{"name":"Korean Journal of Urology","volume":"56 7","pages":"487-97"},"PeriodicalIF":0.0,"publicationDate":"2015-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4111/kju.2015.56.7.487","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34008005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-06-01Epub Date: 2015-06-02DOI: 10.4111/kju.2015.56.6.461
Yoon Seob Ji, Young Hwii Ko, Phil Hyun Song, Ki Hak Moon
Purpose: We investigated the long-term survival and patient satisfaction with an inflatable penile prosthesis as a treatment for refractory erectile dysfunction (ED).
Materials and methods: Between July 1997 and September 2014, a total of 74 patients underwent implantation of an inflatable penile prosthesis. The present mechanical status of the prosthesis was ascertained by telephone interview and review of medical records, and related clinical factors were analyzed by using Cox proportional hazard regression model. To investigate current status and satisfaction with the devices, novel questionnaires consisting of eight items were administered.
Results: The mean (±standard deviation) age and follow-up period were 57.0±12.2 years and 105.5±64.0 months, respectively. Sixteen patients (21.6%) experienced a mechanical failure and 4 patients (5.4%) experienced a nonmechanical failure at a median follow-up of 98.0 months. Mechanical and overall survival rates of the inflatable penile prosthesis at 5, 10, and 15 years were 93.3%, 76.5%, and 64.8% and 89.1%, 71.4%, and 60.5%, respectively, without a statistically significant correlation with host factors including age, cause of ED, and presence of obesity, hypertension, and diabetes mellitus. Overall, 53 patients (71.6%) completed the questionnaires. The overall patient satisfaction rate was 86.8%, and 83.0% of the patients replied that they intended to repeat the same procedure. Among the 8 items asked, satisfaction with the rigidity of the device received the highest score (90.6%). In contrast, only 60.4% of subjects experienced orgasm.
Conclusions: The results of our study suggest that excellent long-term reliability and high patient satisfaction rates make the implantation of an inflatable penile prosthesis a recommendable surgical treatment for refractory ED.
{"title":"Long-term survival and patient satisfaction with inflatable penile prosthesis for the treatment of erectile dysfunction.","authors":"Yoon Seob Ji, Young Hwii Ko, Phil Hyun Song, Ki Hak Moon","doi":"10.4111/kju.2015.56.6.461","DOIUrl":"https://doi.org/10.4111/kju.2015.56.6.461","url":null,"abstract":"<p><strong>Purpose: </strong>We investigated the long-term survival and patient satisfaction with an inflatable penile prosthesis as a treatment for refractory erectile dysfunction (ED).</p><p><strong>Materials and methods: </strong>Between July 1997 and September 2014, a total of 74 patients underwent implantation of an inflatable penile prosthesis. The present mechanical status of the prosthesis was ascertained by telephone interview and review of medical records, and related clinical factors were analyzed by using Cox proportional hazard regression model. To investigate current status and satisfaction with the devices, novel questionnaires consisting of eight items were administered.</p><p><strong>Results: </strong>The mean (±standard deviation) age and follow-up period were 57.0±12.2 years and 105.5±64.0 months, respectively. Sixteen patients (21.6%) experienced a mechanical failure and 4 patients (5.4%) experienced a nonmechanical failure at a median follow-up of 98.0 months. Mechanical and overall survival rates of the inflatable penile prosthesis at 5, 10, and 15 years were 93.3%, 76.5%, and 64.8% and 89.1%, 71.4%, and 60.5%, respectively, without a statistically significant correlation with host factors including age, cause of ED, and presence of obesity, hypertension, and diabetes mellitus. Overall, 53 patients (71.6%) completed the questionnaires. The overall patient satisfaction rate was 86.8%, and 83.0% of the patients replied that they intended to repeat the same procedure. Among the 8 items asked, satisfaction with the rigidity of the device received the highest score (90.6%). In contrast, only 60.4% of subjects experienced orgasm.</p><p><strong>Conclusions: </strong>The results of our study suggest that excellent long-term reliability and high patient satisfaction rates make the implantation of an inflatable penile prosthesis a recommendable surgical treatment for refractory ED.</p>","PeriodicalId":17819,"journal":{"name":"Korean Journal of Urology","volume":"56 6","pages":"461-5"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4111/kju.2015.56.6.461","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33266749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-06-01Epub Date: 2015-05-27DOI: 10.4111/kju.2015.56.6.455
Taesoo Choi, Koo Han Yoo, Seung-Kwon Choi, Dong Soo Kim, Dong-Gi Lee, Gyeong Eun Min, Seung Hyun Jeon, Hyung-Lae Lee, In-Kyung Jeong
Purpose: The aim of our study was to evaluate the association of several factors with spontaneous stone expulsion, including ureteral stone characteristics (size, location, hydronephrosis, perinephric stranding), types of medications prescribed (α-blocker, low-dose steroid), and other possible demographic and health-history factors (gender, age, serum creatinine, underlying diabetes mellitus [DM], and hypertension).
Materials and methods: A total of 366 patients with ureteral stones were enrolled. All patients underwent watchful waiting without any invasive procedures. Initial diagnoses of ureteral stones were confirmed by computed tomography scans, which were taken at approximately 1-month intervals to check for stone expulsion. Univariate and multivariate analyses were conducted to identify significant factors that contributed to stone expulsion.
Results: Among 366 patients, 335 patients (91.5%) experienced spontaneous stone passage during a mean follow-up period of 2.95±2.62 weeks. The patients were divided into two groups depending on the success of spontaneous stone passage. Univariate analyses revealed that stone location (p=0.003), stone size (p=0.021), and underlying DM (p<0.001) were significant predictors of stone passage. Multivariate analyses confirmed that stone size (p=0.010), stone location (p=0.008), and underlying DM (p=0.003) were independent predictive factors affecting stone passage.
Conclusions: Stone size, location, and underlying DM were confirmed to be significant predictive factors for spontaneous passage of ureteral stones. Urologists should consider active procedures, such as shock wave lithotripsy or ureteroscopy, rather than conservative management in patients presenting with proximally located stones, large ureteral stones, or underlying DM.
{"title":"Analysis of factors affecting spontaneous expulsion of ureteral stones that may predict unfavorable outcomes during watchful waiting periods: What is the influence of diabetes mellitus on the ureter?","authors":"Taesoo Choi, Koo Han Yoo, Seung-Kwon Choi, Dong Soo Kim, Dong-Gi Lee, Gyeong Eun Min, Seung Hyun Jeon, Hyung-Lae Lee, In-Kyung Jeong","doi":"10.4111/kju.2015.56.6.455","DOIUrl":"https://doi.org/10.4111/kju.2015.56.6.455","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of our study was to evaluate the association of several factors with spontaneous stone expulsion, including ureteral stone characteristics (size, location, hydronephrosis, perinephric stranding), types of medications prescribed (α-blocker, low-dose steroid), and other possible demographic and health-history factors (gender, age, serum creatinine, underlying diabetes mellitus [DM], and hypertension).</p><p><strong>Materials and methods: </strong>A total of 366 patients with ureteral stones were enrolled. All patients underwent watchful waiting without any invasive procedures. Initial diagnoses of ureteral stones were confirmed by computed tomography scans, which were taken at approximately 1-month intervals to check for stone expulsion. Univariate and multivariate analyses were conducted to identify significant factors that contributed to stone expulsion.</p><p><strong>Results: </strong>Among 366 patients, 335 patients (91.5%) experienced spontaneous stone passage during a mean follow-up period of 2.95±2.62 weeks. The patients were divided into two groups depending on the success of spontaneous stone passage. Univariate analyses revealed that stone location (p=0.003), stone size (p=0.021), and underlying DM (p<0.001) were significant predictors of stone passage. Multivariate analyses confirmed that stone size (p=0.010), stone location (p=0.008), and underlying DM (p=0.003) were independent predictive factors affecting stone passage.</p><p><strong>Conclusions: </strong>Stone size, location, and underlying DM were confirmed to be significant predictive factors for spontaneous passage of ureteral stones. Urologists should consider active procedures, such as shock wave lithotripsy or ureteroscopy, rather than conservative management in patients presenting with proximally located stones, large ureteral stones, or underlying DM.</p>","PeriodicalId":17819,"journal":{"name":"Korean Journal of Urology","volume":"56 6","pages":"455-60"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4111/kju.2015.56.6.455","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33266748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-06-01DOI: 10.4111/kju.2015.56.6.409
Jae Heon Kim, Yun Seob Song
Stem cells have the ability to propagate through self renewal and generate mature cells of multiple lineages through differentiation [1,2]. Explorations of the potential value of stem cell therapy in urology have included studies of bladder dysfunction, erectile dysfunction (ED), stress urinary incontinence (SUI), and prostate and bladder cancer. Only a few pilot human translational studies study of stress incontinence and diabetes induced ED have been reported. Recently, Alwaal et al. [3] introduced the current status of stem cell treatment in benign urological diseases including ED, Peyronie disease, infertility and SUI. The prowess of stem cell therapy has been indicated in bladder dysfunction models including bladder outlet obstruction, chronic ischemia, diabetes, cryo-injury, pelvic nerve injury, and spinal cord injury (SCI). Except for cryo-injury and pelvic nerve injury, models have demonstrated overactive urodynamics, indicative of improved inter-contraction interval and maximal voiding pressure [1,2]. Underactivity models including cryo-injury and pelvic nerve injury models have demonstrated improvements of intravesical pressure. Marked smooth muscle differentiation has been reported in three studies. Concerning SCI-induced bladder dysfunction, a meta-analysis affirmed that stem cell-based cell therapyproduces partial bladder recovery including improvement of voiding pressure, inter-contraction interval, and residual urine [4]. For ED, stem cell injection into the corpus cavernosum or periprostatic implantation improves erectile functions in diabetic, hyperlipidemic rat models, as well as in neurogenic ED models. A recent meta-analysis indicated that stem cell therapy in neurogenic ED models recovers erectile function [5]. Periprostatic implantation with acellular scaffolds can promote cavernous nerve regeneration, but is less effective for smooth muscle cell recovery. ED models have provided evidence that homogenous clonal stem cells can overcome the inherent impediment of the heterogenous nature of isolated cells, providing optimism of the clinical value of stem cell therapy of ED. Successful ED therapy primarily relies on the improvement of functional and histological components. No direct evidence concerning the identification of stem cell differentiation has yet been described, suggesting the importance of paracrine action as a principle therapeutic mechanism in stem cell therapy of ED. Currently, two phase I-II stem cell clinical trials are recruiting patients with ED. One trial (NCT01089387) seeks to evaluate the efficacy of intracavernous injection of bone marrow stem cells in postradical prostatectomy patients. The other trial (NCT01601353) will evaluate the effect of intracavernous injection of adipose-derived stem cells in organic ED (vasculogenicand neural). Relative to other fields in urology, research on stem cell-related gene therapy for ED has been less robust. The few studies to date have involved stem cells
{"title":"Current status of stem cell therapy in urology.","authors":"Jae Heon Kim, Yun Seob Song","doi":"10.4111/kju.2015.56.6.409","DOIUrl":"https://doi.org/10.4111/kju.2015.56.6.409","url":null,"abstract":"Stem cells have the ability to propagate through self renewal and generate mature cells of multiple lineages through differentiation [1,2]. Explorations of the potential value of stem cell therapy in urology have included studies of bladder dysfunction, erectile dysfunction (ED), stress urinary incontinence (SUI), and prostate and bladder cancer. Only a few pilot human translational studies study of stress incontinence and diabetes induced ED have been reported. Recently, Alwaal et al. [3] introduced the current status of stem cell treatment in benign urological diseases including ED, Peyronie disease, infertility and SUI. \u0000 \u0000The prowess of stem cell therapy has been indicated in bladder dysfunction models including bladder outlet obstruction, chronic ischemia, diabetes, cryo-injury, pelvic nerve injury, and spinal cord injury (SCI). Except for cryo-injury and pelvic nerve injury, models have demonstrated overactive urodynamics, indicative of improved inter-contraction interval and maximal voiding pressure [1,2]. Underactivity models including cryo-injury and pelvic nerve injury models have demonstrated improvements of intravesical pressure. Marked smooth muscle differentiation has been reported in three studies. Concerning SCI-induced bladder dysfunction, a meta-analysis affirmed that stem cell-based cell therapyproduces partial bladder recovery including improvement of voiding pressure, inter-contraction interval, and residual urine [4]. \u0000 \u0000For ED, stem cell injection into the corpus cavernosum or periprostatic implantation improves erectile functions in diabetic, hyperlipidemic rat models, as well as in neurogenic ED models. A recent meta-analysis indicated that stem cell therapy in neurogenic ED models recovers erectile function [5]. Periprostatic implantation with acellular scaffolds can promote cavernous nerve regeneration, but is less effective for smooth muscle cell recovery. ED models have provided evidence that homogenous clonal stem cells can overcome the inherent impediment of the heterogenous nature of isolated cells, providing optimism of the clinical value of stem cell therapy of ED. \u0000 \u0000Successful ED therapy primarily relies on the improvement of functional and histological components. No direct evidence concerning the identification of stem cell differentiation has yet been described, suggesting the importance of paracrine action as a principle therapeutic mechanism in stem cell therapy of ED. Currently, two phase I-II stem cell clinical trials are recruiting patients with ED. One trial (NCT01089387) seeks to evaluate the efficacy of intracavernous injection of bone marrow stem cells in postradical prostatectomy patients. The other trial (NCT01601353) will evaluate the effect of intracavernous injection of adipose-derived stem cells in organic ED (vasculogenicand neural). \u0000 \u0000Relative to other fields in urology, research on stem cell-related gene therapy for ED has been less robust. The few studies to date have involved stem cells ","PeriodicalId":17819,"journal":{"name":"Korean Journal of Urology","volume":"56 6","pages":"409-11"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4111/kju.2015.56.6.409","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33392995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-06-01Epub Date: 2015-05-27DOI: 10.4111/kju.2015.56.6.422
Wan Song, Hwang Gyun Jeon
The incidence of cancer is sharply increasing. Cancer is a leading cause of death as well as a significant burden on society. The incidence of urological cancer has shown a higher than average increase and will become an important concern in the future. Therefore, an overall and accurate understanding of the incidence of urological cancer is essential. In this study, which was based on the Korea National Cancer Incidence Database, annual incident cases, age-standardized incidence rates, annual percentage change (APC), and distribution by age group were examined in kidney, bladder, and prostate cancers, respectively. From 1999 to 2011, the total number of each type of urological cancer was as follows: kidney cancer (32,600 cases, 25.5%), bladder cancer (37,950 cases, 29.7%), and prostate cancer (57,332 cases, 44.8%). The age-standardized incidence rates of prostate cancer showed a significant increase with an APC of 12.3% in males. Kidney cancer gradually increased with an APC of 6.0% for both sexes and became the second most frequent urological cancer after 2008. Bladder cancer showed no significant change with an APC of -0.2% for both sexes and has decreased slightly since 2007. The distribution of kidney cancer according to age showed two peaks in the 50- to 54-year-old and 65- to 69-year-old age groups. Bladder and prostate cancers occurred mostly in the 70- to 74-year-old age group. The proportions of male to female were 2.5:1 in kidney cancer and 5.6:1 in bladder cancer. We have summarized the incidence trends of kidney, bladder, and prostate cancers and have provided useful information for screening and management of these cancers in the future.
{"title":"Incidence of kidney, bladder, and prostate cancers in Korea: An update.","authors":"Wan Song, Hwang Gyun Jeon","doi":"10.4111/kju.2015.56.6.422","DOIUrl":"https://doi.org/10.4111/kju.2015.56.6.422","url":null,"abstract":"<p><p>The incidence of cancer is sharply increasing. Cancer is a leading cause of death as well as a significant burden on society. The incidence of urological cancer has shown a higher than average increase and will become an important concern in the future. Therefore, an overall and accurate understanding of the incidence of urological cancer is essential. In this study, which was based on the Korea National Cancer Incidence Database, annual incident cases, age-standardized incidence rates, annual percentage change (APC), and distribution by age group were examined in kidney, bladder, and prostate cancers, respectively. From 1999 to 2011, the total number of each type of urological cancer was as follows: kidney cancer (32,600 cases, 25.5%), bladder cancer (37,950 cases, 29.7%), and prostate cancer (57,332 cases, 44.8%). The age-standardized incidence rates of prostate cancer showed a significant increase with an APC of 12.3% in males. Kidney cancer gradually increased with an APC of 6.0% for both sexes and became the second most frequent urological cancer after 2008. Bladder cancer showed no significant change with an APC of -0.2% for both sexes and has decreased slightly since 2007. The distribution of kidney cancer according to age showed two peaks in the 50- to 54-year-old and 65- to 69-year-old age groups. Bladder and prostate cancers occurred mostly in the 70- to 74-year-old age group. The proportions of male to female were 2.5:1 in kidney cancer and 5.6:1 in bladder cancer. We have summarized the incidence trends of kidney, bladder, and prostate cancers and have provided useful information for screening and management of these cancers in the future. </p>","PeriodicalId":17819,"journal":{"name":"Korean Journal of Urology","volume":"56 6","pages":"422-8"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4111/kju.2015.56.6.422","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33266743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-06-01Epub Date: 2015-06-02DOI: 10.4111/kju.2015.56.6.466
Chunwoo Lee, Dalsan You, In Gab Jeong, Jun Hyuk Hong, Myung-Soo Choo, Hanjong Ahn, Tai Young Ahn, Choung-Soo Kim
Purpose: To assess the rates of infectious complications before and after the change of prophylactic antibiotic regimens in prostate needle biopsy.
Materials and methods: The records of 5,577 patients who underwent prostate needle biopsy at Asan Medical Center between August 2005 and July 2012 were retrospectively reviewed. Group 1 (n=1,743) included patients treated between 2005 and 2009 with fluoroquinolone for 3 days, group 2 (n=2,723) included those treated between 2009 and 2012 with ceftriaxone once before the biopsy and fluoroquinolone before biopsy and continue therapy for 3 days, and group 3 (n=1,111) received the same treatment for more than 7 days after the biopsy. Univariable and multivariable logistic regression models addressed risk factors associated with infectious complication after prostate needle biopsy.
Results: Infectious complication after prostate needle biopsy developed in 18 (group 1), seven (group 2), and two patients (group 3) (p=0.001). In group 1, seven patients with infectious complication had positive blood cultures and harbored fluoroquinolone-resistant Escherichia coli, four had ceftriaxone susceptible isolates, and three had extended spectrum beta-lactamase-positive E. coli. Two patients in group 1 required intensive care because of septic shock. In multivariable analysis, the patients with combination of fluoroquinolone and ceftriaxone had significantly lower infectious complication rate than the fluoroquinolon alone (p=0.003).
Conclusions: Antibiotic prophylaxis with ceftriaxone and fluoroquinolone before prostate needle biopsy decreased the risk of potentially serious infectious complications.
{"title":"Antibiotic prophylaxis with intravenous ceftriaxone and fluoroquinolone reduces infectious complications after transrectal ultrasound-guided prostatic biopsy.","authors":"Chunwoo Lee, Dalsan You, In Gab Jeong, Jun Hyuk Hong, Myung-Soo Choo, Hanjong Ahn, Tai Young Ahn, Choung-Soo Kim","doi":"10.4111/kju.2015.56.6.466","DOIUrl":"https://doi.org/10.4111/kju.2015.56.6.466","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the rates of infectious complications before and after the change of prophylactic antibiotic regimens in prostate needle biopsy.</p><p><strong>Materials and methods: </strong>The records of 5,577 patients who underwent prostate needle biopsy at Asan Medical Center between August 2005 and July 2012 were retrospectively reviewed. Group 1 (n=1,743) included patients treated between 2005 and 2009 with fluoroquinolone for 3 days, group 2 (n=2,723) included those treated between 2009 and 2012 with ceftriaxone once before the biopsy and fluoroquinolone before biopsy and continue therapy for 3 days, and group 3 (n=1,111) received the same treatment for more than 7 days after the biopsy. Univariable and multivariable logistic regression models addressed risk factors associated with infectious complication after prostate needle biopsy.</p><p><strong>Results: </strong>Infectious complication after prostate needle biopsy developed in 18 (group 1), seven (group 2), and two patients (group 3) (p=0.001). In group 1, seven patients with infectious complication had positive blood cultures and harbored fluoroquinolone-resistant Escherichia coli, four had ceftriaxone susceptible isolates, and three had extended spectrum beta-lactamase-positive E. coli. Two patients in group 1 required intensive care because of septic shock. In multivariable analysis, the patients with combination of fluoroquinolone and ceftriaxone had significantly lower infectious complication rate than the fluoroquinolon alone (p=0.003).</p><p><strong>Conclusions: </strong>Antibiotic prophylaxis with ceftriaxone and fluoroquinolone before prostate needle biopsy decreased the risk of potentially serious infectious complications.</p>","PeriodicalId":17819,"journal":{"name":"Korean Journal of Urology","volume":"56 6","pages":"466-72"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4111/kju.2015.56.6.466","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33271899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-06-01Epub Date: 2015-05-27DOI: 10.4111/kju.2015.56.6.473
Matthew Lee, Ziho Lee, Daniel Eun
A patient with a complete right ureteral triplication presented with recurrent pyelonephritis and flank pain that was refractory to medical management. Evaluation showed that the atrophic upper-most renal moiety had been chronically obstructed and was associated with a dilated ureter. Intraureteral and intravenous indocyanine green (ICG) were used as real-time contrast agents intraoperatively to facilitate right robotic partial nephroureterectomy of the diseased system. Intraureteral ICG was used to accurately distinguish the pathologic ureter and associated renal pelvis from its normal counterparts. Intravenous ICG was used to assess perfusion in the right kidney and delineate the margins of diseased renal parenchyma.
{"title":"Intraureteral and intravenous indocyanine green to facilitate robotic partial nephroureterectomy in a patient with complete ureteral triplication.","authors":"Matthew Lee, Ziho Lee, Daniel Eun","doi":"10.4111/kju.2015.56.6.473","DOIUrl":"https://doi.org/10.4111/kju.2015.56.6.473","url":null,"abstract":"<p><p>A patient with a complete right ureteral triplication presented with recurrent pyelonephritis and flank pain that was refractory to medical management. Evaluation showed that the atrophic upper-most renal moiety had been chronically obstructed and was associated with a dilated ureter. Intraureteral and intravenous indocyanine green (ICG) were used as real-time contrast agents intraoperatively to facilitate right robotic partial nephroureterectomy of the diseased system. Intraureteral ICG was used to accurately distinguish the pathologic ureter and associated renal pelvis from its normal counterparts. Intravenous ICG was used to assess perfusion in the right kidney and delineate the margins of diseased renal parenchyma. </p>","PeriodicalId":17819,"journal":{"name":"Korean Journal of Urology","volume":"56 6","pages":"473-6"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4111/kju.2015.56.6.473","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33271900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-06-01Epub Date: 2015-05-27DOI: 10.4111/kju.2015.56.6.412
Hyun Chul Chung, In Kap Ko, Anthony Atala, James J Yoo
The prevalence of renal disease continues to increase worldwide. When normal kidney is injured, the damaged renal tissue undergoes pathological and physiological events that lead to acute and chronic kidney diseases, which frequently progress to end stage renal failure. Current treatment of these renal pathologies includes dialysis, which is incapable of restoring full renal function. To address this issue, cell-based therapy has become a potential therapeutic option to treat renal pathologies. Recent development in cell therapy has demonstrated promising therapeutic outcomes, in terms of restoration of renal structure and function impaired by renal disease. This review focuses on the cell therapy approaches for the treatment of kidney diseases, including various cell sources used, as well recent advances made in preclinical and clinical studies.
{"title":"Cell-based therapy for kidney disease.","authors":"Hyun Chul Chung, In Kap Ko, Anthony Atala, James J Yoo","doi":"10.4111/kju.2015.56.6.412","DOIUrl":"https://doi.org/10.4111/kju.2015.56.6.412","url":null,"abstract":"<p><p>The prevalence of renal disease continues to increase worldwide. When normal kidney is injured, the damaged renal tissue undergoes pathological and physiological events that lead to acute and chronic kidney diseases, which frequently progress to end stage renal failure. Current treatment of these renal pathologies includes dialysis, which is incapable of restoring full renal function. To address this issue, cell-based therapy has become a potential therapeutic option to treat renal pathologies. Recent development in cell therapy has demonstrated promising therapeutic outcomes, in terms of restoration of renal structure and function impaired by renal disease. This review focuses on the cell therapy approaches for the treatment of kidney diseases, including various cell sources used, as well recent advances made in preclinical and clinical studies. </p>","PeriodicalId":17819,"journal":{"name":"Korean Journal of Urology","volume":"56 6","pages":"412-21"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4111/kju.2015.56.6.412","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33266742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-06-01Epub Date: 2015-05-28DOI: 10.4111/kju.2015.56.6.429
Ji Sung Shim, Hoon Choi, Tae Il Noh, Jong Hyun Tae, Sung Goo Yoon, Seok Ho Kang, Jae Hyun Bae, Hong Seok Park, Jae Young Park
Purpose: This study was designed to estimate the value of a second transurethral resection of bladder tumor (TURBT) procedure in patients with initially diagnosed T1 high-grade bladder cancer.
Materials and methods: Between August 2009 and January 2013, a total of 29 patients with T1 high-grade bladder cancer prospectively underwent a second TURBT procedure. Evaluation included the presence of previously undetected residual tumor, changes to histopathological staging or grading, and tumor location. Recurrence-free and progression-free survival curves were generated to compare the prognosis between the groups with and without residual lesions by use of the Kaplan-Meier method.
Results: Of 29 patients, 22 patients (75.9%) had residual disease after the second TURBT. Staging was as follows: no tumor, 7 (24.1%); Ta, 5 (17.2%); T1, 6 (20.7%); Tis, 6 (20.7%); Ta+Tis, 1 (3.4%); T1+Tis, 1 (3.4%); and ≥T2, 3 (10.3%). The muscle layer was included in the surgical specimen after the initial TURBT in 24 patients (82.7%). In three patients whose cancer was upstaged to pT2 after the second TURBT, the initial surgical specimen contained the muscle layer. In the group with residual lesions, the 3-year recurrence-free survival and 3-year progression-free survival rates were 50% and 66.9%, respectively, whereas these rates were 68.6% and 68.6%, respectively, in the group without residual lesions. This difference was not statistically significant.
Conclusions: Initial TURBT does not seem to be enough to control T1 high-grade bladder cancer. Therefore, a routine second TURBT procedure should be recommended in patients with T1 high-grade bladder cancer to accomplish adequate tumor resection and to identify patients who may need to undergo prompt cystectomy.
{"title":"The clinical significance of a second transurethral resection for T1 high-grade bladder cancer: Results of a prospective study.","authors":"Ji Sung Shim, Hoon Choi, Tae Il Noh, Jong Hyun Tae, Sung Goo Yoon, Seok Ho Kang, Jae Hyun Bae, Hong Seok Park, Jae Young Park","doi":"10.4111/kju.2015.56.6.429","DOIUrl":"https://doi.org/10.4111/kju.2015.56.6.429","url":null,"abstract":"<p><strong>Purpose: </strong>This study was designed to estimate the value of a second transurethral resection of bladder tumor (TURBT) procedure in patients with initially diagnosed T1 high-grade bladder cancer.</p><p><strong>Materials and methods: </strong>Between August 2009 and January 2013, a total of 29 patients with T1 high-grade bladder cancer prospectively underwent a second TURBT procedure. Evaluation included the presence of previously undetected residual tumor, changes to histopathological staging or grading, and tumor location. Recurrence-free and progression-free survival curves were generated to compare the prognosis between the groups with and without residual lesions by use of the Kaplan-Meier method.</p><p><strong>Results: </strong>Of 29 patients, 22 patients (75.9%) had residual disease after the second TURBT. Staging was as follows: no tumor, 7 (24.1%); Ta, 5 (17.2%); T1, 6 (20.7%); Tis, 6 (20.7%); Ta+Tis, 1 (3.4%); T1+Tis, 1 (3.4%); and ≥T2, 3 (10.3%). The muscle layer was included in the surgical specimen after the initial TURBT in 24 patients (82.7%). In three patients whose cancer was upstaged to pT2 after the second TURBT, the initial surgical specimen contained the muscle layer. In the group with residual lesions, the 3-year recurrence-free survival and 3-year progression-free survival rates were 50% and 66.9%, respectively, whereas these rates were 68.6% and 68.6%, respectively, in the group without residual lesions. This difference was not statistically significant.</p><p><strong>Conclusions: </strong>Initial TURBT does not seem to be enough to control T1 high-grade bladder cancer. Therefore, a routine second TURBT procedure should be recommended in patients with T1 high-grade bladder cancer to accomplish adequate tumor resection and to identify patients who may need to undergo prompt cystectomy.</p>","PeriodicalId":17819,"journal":{"name":"Korean Journal of Urology","volume":"56 6","pages":"429-34"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4111/kju.2015.56.6.429","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33266744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-06-01Epub Date: 2015-06-02DOI: 10.4111/kju.2015.56.6.435
Gianluigi Taverna, Fabio Grizzi, Piergiuseppe Colombo, Mauro Seveso, Guido Giusti, Silvia Proietti, Girolamo Fiorini, Giovanni Lughezzani, Paolo Casale, Nicolò Buffi, Massimo Lazzari, Giorgio Guazzoni
Purpose: Prostate cancer is the most frequent cancer in men in Europe. A major focus in urology is the identification of new biomarkers with improved accuracy in patients with low-risk prostate cancer. Here, we evaluated two-dimensional neovascular complexity in prostate tumor and nontumor biopsy cores by use of a computer-aided image analysis system and assessed the correlations between the results and selected clinical and pathological parameters of prostate carcinoma.
Materials and methods: A total of 280 prostate biopsy sections from a homogeneous series of 70 patients with low-risk prostate cancer (Gleason score 3+3, prostate-specific antigen [PSA]<10 ng/mL, and clinical stage T1c) who underwent systematic biopsy sampling and subsequent radical prostatectomy were analyzed. For each biopsy, 2-µm sections were treated with CD34 antibodies and were digitized by using an image analysis system that automatically estimates the surface fractal dimension.
Results: Our results showed that biopsy sections without cancer were significantly more vascularized than were tumors. No correlations were found between the vascular surface fractal dimension and patient's age, PSA and free-to-total PSA ratios, pathological stage, Gleason score, tumor volume, vascular invasion, capsular penetration, surgical margins, and biochemical recurrence.
Conclusions: The value of angiogenesis in prostate cancer is still controversial. Our findings suggest that low-risk prostate cancer tissues are less vascularized than are nontumor tissues. Further studies are necessary to understand whether angiogenesis is a hallmark of intermediate- and high-risk prostate cancer.
{"title":"Two-dimensional neovascular complexity is significantly higher in nontumor prostate tissue than in low-risk prostate cancer.","authors":"Gianluigi Taverna, Fabio Grizzi, Piergiuseppe Colombo, Mauro Seveso, Guido Giusti, Silvia Proietti, Girolamo Fiorini, Giovanni Lughezzani, Paolo Casale, Nicolò Buffi, Massimo Lazzari, Giorgio Guazzoni","doi":"10.4111/kju.2015.56.6.435","DOIUrl":"https://doi.org/10.4111/kju.2015.56.6.435","url":null,"abstract":"<p><strong>Purpose: </strong>Prostate cancer is the most frequent cancer in men in Europe. A major focus in urology is the identification of new biomarkers with improved accuracy in patients with low-risk prostate cancer. Here, we evaluated two-dimensional neovascular complexity in prostate tumor and nontumor biopsy cores by use of a computer-aided image analysis system and assessed the correlations between the results and selected clinical and pathological parameters of prostate carcinoma.</p><p><strong>Materials and methods: </strong>A total of 280 prostate biopsy sections from a homogeneous series of 70 patients with low-risk prostate cancer (Gleason score 3+3, prostate-specific antigen [PSA]<10 ng/mL, and clinical stage T1c) who underwent systematic biopsy sampling and subsequent radical prostatectomy were analyzed. For each biopsy, 2-µm sections were treated with CD34 antibodies and were digitized by using an image analysis system that automatically estimates the surface fractal dimension.</p><p><strong>Results: </strong>Our results showed that biopsy sections without cancer were significantly more vascularized than were tumors. No correlations were found between the vascular surface fractal dimension and patient's age, PSA and free-to-total PSA ratios, pathological stage, Gleason score, tumor volume, vascular invasion, capsular penetration, surgical margins, and biochemical recurrence.</p><p><strong>Conclusions: </strong>The value of angiogenesis in prostate cancer is still controversial. Our findings suggest that low-risk prostate cancer tissues are less vascularized than are nontumor tissues. Further studies are necessary to understand whether angiogenesis is a hallmark of intermediate- and high-risk prostate cancer.</p>","PeriodicalId":17819,"journal":{"name":"Korean Journal of Urology","volume":"56 6","pages":"435-42"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4111/kju.2015.56.6.435","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33266745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}